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Abstract:  Smoking  cessation  aids  (nicotine  replacement  products  and  anti-depressant 
medication)  have  been  proven  to  double quitting rates compared to  placebo in  several 
randomized  controlled  trials.  But  the  high  initial  cost  of  cessation  aids  might  create  a 
financial  barrier  to  cessation  for  low-income  smokers.  In  the  U.S.,  Medicaid  provides 
health  insurance  coverage  to  low-income  people,  and  in  some  states  covers  smoking 
cessation products. This paper uses nationally representative data of the U.S. to examine 
how the Medicaid coverage of cessation aids affect smoking behavior. The results indicate 
the  Medicaid  coverage  of  cessation  products  is  positively  associated  with  successful 
quitting among women aged 18–44. 
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1. Introduction 
 
According to the Current Population Survey (CPS)—Tobacco Usage Supplement (TUS) 1992–2003 
in the U.S. 26% of Medicaid recipients (age 15 to 90) are everyday smokers, compared to 16% for the 
general  population.  The  probability  of  smoking  among  Medicaid  recipients  is  approximately  50% 
higher than among the non-Medicaid population.  
Most smokers want to quit. CPS-TUS data reveal that 73% current smokers have ever tried to quit 
for at least one day. In a typical year, 45% of smokers try to quit smoking. However, fewer than 5% 
succeed  in  quitting  each  year  [1].  Smokers  can  take  Tobacco  Dependence  Treatments  (TDT)  to 
increase  quitting  success  rates.  There  are  two  basic  forms  of  TDT:  pharmacotherapy  treatments 
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(nicotine  replacement  products  and  anti-depressant  medication)  and  counseling  service.  A  
meta-analysis study [2] suggests nicotine replacement therapy (NRT) doubles successful quitting rates. 
Other  studies  [3,4]  have  shown  evidence  that  nicotine  replacement  therapy,  in  combination  with 
counseling services is more successful than drug therapy alone. Counseling services may include stress 
management, weight control, tips for preventing relapse, and other behavioral or psychological support. 
But TDT costs money. Among smokers who have never used any NRT products, cost is the most 
frequently cited reason [5]. For example, a 30 day supply of skin patches will cost about $112. Since 
Medicaid recipients have low incomes, the high initial cost of treatments might create a barrier to using 
TDT for cessation [6]. Providing coverage of TDT would overcome the financial barrier for smokers 
interested in quitting and possibly help to increase successful smoking cessation rate. 
This  study  applies  a  nationally  representative  large  dataset  to  examine  in  detail  how  Medicaid 
coverage of TDT affects smoking cessation. First, a descriptive analysis examines whether usage of 
TDT among Medicaid recipients differs in the states with and without TDT coverage. Second, the 
sample is divided into four groups by age and gender, and separate regression is run for each group to 
investigate differences in smokers’ responsiveness to TDT coverage. Finally, state fixed effects models 
are estimated to control for unobserved differences across states. The study also adopts an alternative 
approach by using state anti-smoking sentiment index explicitly to solve potential multicollinearity 
problem in state fixed effects models. 
 
2. Medicaid Background  
 
Medicaid was established in 1965 to provide health care service to low-income American families. 
There are three kinds of Medicaid recipients: low-income children and women; the disabled; and the 
low-income elderly. Each state administers its own programs under broad federal guidelines. Medicaid 
is jointly financed by the federal and state governments. The federal matching rate depends on state's 
average per capita income level. Federal government reimburses states at a lower rate if the state has 
higher per capita income. By law, federal matching rate is between 50% and 83%. In 2002, the average 
matching rate of federal funds is 57% overall [7]. Smoking-caused Medicaid costs have increased from 
$12.9 billion in 1993 to $27.2 billion in 2001 [8,9]. According to National Commission on Prevention 
Priorities, smoking is one of the three preventive services that are cost saving [10].  
By federal rules, states may choose whether or not to cover the costs of TDT. Each state might have 
different measures of cost and benefit before deciding whether offering coverage of TDT. The costs 
include pretreatment screening to identify smokers, advising or motivating smokers to quit, actual cost 
of NRT products, costs of physicians, nurses and counseling providers. Most benefits from smoking 
cessation occur over a long period of time, like reducing the risks of developing lung cancer, heart 
attack and stroke. In the short-run, benefits include decrease of coughing and shortness of breath [11]. 
For pregnant women, smoking cessation leads to fewer low birth weight infants. Consequently, health 
care expenditures will be reduced. 
Lawmakers from tobacco-growing states (Kentucky, North Carolina, Tennessee, and Virginia) are 
less likely to vote in favor of tobacco control legislation because doing so might hurt the economy of 
these  states  or  just  because  of  political  reasons—they  do  not  want  to  alienate  important  political Int. J. Environ. Res. Public Health 2009, 6                 
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constituencies—tobacco farmers and others employed in the tobacco industry. Flynn et al. [12] find 
that  legislators  in  Vermont  were  almost  21  times  more  likely  to  intend  to  vote  for  cigarette  tax 
increases  than  lawmakers  in  North  Carolina.  Similarly,  legislators  in  Kentucky  did  not  consider 
covering the smoking cessation aids by the state Medicaid plan until 2006 [13]. 
 
3. Literature Review 
 
Several studies  have examined the effect  of insurance coverage of TDT on smoking cessation.  
Curry et al. [14] compared the cessation behavior of smokers who enrolled in four different insurance 
plans  in  Washington  State.  The  four  plans  comprised  of  different  combinations  of  co-insurance:  
(1)  50%  coverage  of  both  behavioral  programs  and nicotine-replacement therapy (NRT);  (2) 50% 
coverage of behavioral programs and full coverage of NRT; (3) full coverage of behavioral programs 
and 50% coverage of NRT; 4) full coverage of both behavioral programs and NRT. They find out, on 
average, 2.8% smokers under full coverage quit smoking per year, compared to 1.9% smokers quitting 
under the cost-sharing plans.  
Boyle et al. [15] studied the effect of a new health plan in Minnesota covering NRT (gum and 
patch) and Zyban
® (an anti-depressant medication) on the use of these products and quitting rate. They 
find that smokers in plans that covered the cost of smoking-cessation pharmacy products were no more 
likely to quit than those in plans without the benefit. One possible reason is the knowledge gap as the 
authors find only 30% of the smokers whose plan included the benefit reported knowing it. Similarly, a 
report by the Centers for Disease Control and Prevention [16] finds that only 28% of states that offer 
TDT coverage to Medicaid recipients inform their beneficiaries of these benefits. 
Schauffer et al. [17] conducted a randomized experiment among smokers enrolled in HMOs in 
California. The nicotine patch, gum, and group counseling are covered in the treatment group. They 
find the quitting rate among smokers in treatment group was 18% over 12 months, compared to 13% in 
the control group (odds ratio 1.6). 
The common shortcoming of the above three studies is they only focus on one state. The results 
therefore  may  not  be  generalized  to  the  whole  population.  Using  Pregnancy  Risk  Assessment 
Monitoring System data from 15 states, Peterson et al. [18] studied how Medicaid coverage of TDT 
would  affect  smoking  for  pregnant  women.  They  find  women  in  states  with  extensive  coverage  
were 60% more likely to quit smoking than those in states with no coverage. The evidence may be 
biased because there may have been other state level factors, such as cigarette taxes, anti-smoking 
sentiment, that are correlated with the level of Medicaid coverage, and also affect smokers’ decisions 
to quit or not. For example, Medicaid in Utah covers all five forms of medication treatments, but 
people in Utah also hold strong opinions against smoking. Medicaid in Kentucky does not cover any 
medication  treatment,  but  Kentucky  also  has  one  of  the  lowest  cigarette  taxes  in  the  States.  
Over 70 years, the cigarette tax in Kentucky has only risen by a penny in nominal terms, from $0.02  
in 1936 to $0.03 in 2005.  
This study includes both state and year fixed effects in the models. The state fixed effects control for 
constant differences across states that are time-invariant, like anti-smoking sentiment. The year fixed 
effects account for factors that vary uniformly over time across states. Int. J. Environ. Res. Public Health 2009, 6                 
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4. Data and Model  
 
The data of TDT coverage by each state’s Medicaid program are from the Centers for Disease 
Control and Prevention [19]. TDT consists of medication and counseling. Medication includes nicotine 
nasal  spray,  nicotine  inhaler,  nicotine  patch,  nicotine  gum,  and  Zyban  (or  generic  bupropion). 
Counseling service includes group, individual, and telephone counseling. In 2005, 42 state Medicaid 
programs reported offering coverage for at least one form of tobacco-dependence treatment. A TDT 
coverage index is constructed to measure the extensiveness of coverage. The index is a simple tally of 
the number of products and programs covered under each state’s Medicaid program. This index varies 
from 0 to 8. Figure 1 displays the distribution of Medicaid coverage of TDT across states in 2002. 
Among the 50 states and the District of Columbia in this analysis, 11 states had no coverage of any 
cessation aids. Tobacco growing states such as Kentucky, Georgia, and Tennessee were less likely to 
cover medication treatments for Medicaid smokers than other states. Their TDT coverage indices were 
quite low—0s for Georgia and Tennessee and 2 for Kentucky.  
Figure 1. Medicaid Coverage of Tobacco Dependence Treatments in 2002. 
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The  Current  Population  Survey—Tobacco  Use  Supplements  (CPS-TUS)  is  a  nationally 
representative survey and was conducted by the US Census Bureau, sponsored by National Cancer 
Institute and, since 2001, the Centers for Disease Control and Prevention. The surveys were conducted 
in  September  of  1992,  1995,  1998,  January  and  May  of  1993,  1996,  1999,  June  and  November  
of 2001, 2003 and February of 2002, 2003. Each survey provides a sample of over 100,000 individuals 
aged 15 years and older in a given survey period, with detailed economic and demographic information 
from respondents. In particular, the data contain information on respondents' cigarette smoking history 
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and  current  smoking  status.  CPS  March  Supplement  data  provide  detailed  information  on  health 
insurance  coverage  including  Medicaid.  In  CPS  survey,  each  household  is  interviewed  for  four 
consecutive months, then dropped for eight months, then interviewed again for four more months, then 
dropped  permanently.  It  is  convenient  to  merge  part  of  Tobacco  Usage  Supplements  with  March 
Supplements using each individual's identification number.  
The sample is restricted to those who were Medicaid recipients and were smoking 12 months ago. 
Those who were not smoking at the survey date are defined as quitting in the past year. After dropping 
observations  with  missing  values,  we  have a pooled sample of 5,323 individuals.  Respondents  of  
age 15–17 are excluded because NRT is not recommended as a component of pediatric tobacco-use 
interventions  in  the  2008  Public  Health  Service  guideline  [4].  The  definitions  and  means  of  all 
variables are presented in Table 1. The average quitting rate is 9.8%.  
The basic econometric model as below: 
Y = 0 + 1TDT + 2Cigarette Tax + 3X + 4T + e  (1)  
Y = 1 if a smoker quits smoking in the past year and Y=0 if she or he continues to smoke. TDT is 
the tobacco-dependence treatments coverage index that varies across states and years. X is a vector of 
individual  characteristics,  including  sex,  age,  age  squared,  race,  household  size,  family  income, 
education, employment status, marital status and the duration of smoking habits. T includes survey 
month dummies and year fixed effects.  
However, coverage of cessation products is correlated with other state-level characteristics that also 
affect  smoking  behavior. For  example,  Medicaid  programs  in  states  with  stronger anti -smoking 
sentiment are likely to cover smoking cessation aids. In order to control for unobserved characteristics 
across states, state fixed  effects (a set of state dummy variables)  are included in the model. This 
method may involve problems of multicollinearity between  TDT index and state/year dummies when 
TDT coverage does not change much in a given state over time. Serious collinearity can lead to very 
high  standard  errors  of  estimated  coefficients.  The  coefficients  could  have  the  wrong  signs  or 
implausible magnitudes or change dramatically with small changes in data [20]. The Variance Inflation 
Factor  (VIF)  is  an  indicator  to  detect   multicollinearity  of  an  independent  variable  with   other 
explanatory variables. VIF  equals  1/(1-R
2),  where  R
2  is  the  R-squared  for  the  regression  of  that 
independent variable on all the other independent variables. There is no formal result that proves when 
a  VIF  is  too  big,  but  as  a  common  rule  of  thumb,  a  value  of  VIF  above  10  suggests  that 
multicollinearity will present problems [21]. In our sample, a regression of TDT coverage on state 
dummies and year dummies for years yields an R
2 of 0.92. Thus, the VIF for TDT coverage is 12.5, 
which suggests multicollinearity is potentially a serious problem. In addition, the inclusion of state 
fixed effects accounts for any state-specific factor that is constant. Since anti-smoking sentiment may 
change  over  time,  the  use  of  state  fixed  effects  may  not  completely  account  for  unobserved 
determinants of smoking. As a remedy, a state anti-smoking sentiment index [22,23] is used to replace 
the state fixed effects in an alternative model. 
The key independent variable is TDT. The coefficient on this term will tell us for those covered by 
Medicaid, how the treatment coverage would affect smoking cessation. The sample is divided into four 
groups based on age and gender: women aged 18–44; women aged 45 or older; men aged 18–44; men 
aged 45 or older. Separate regressions are run for each group. Previous studies have found that young Int. J. Environ. Res. Public Health 2009, 6                 
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adult smokers were most likely to attempt to quit [24] and females were more likely to use smoking 
cessation aids in a quit attempt [25]. Therefore, it is reasonable to think that TDT coverage might work 
differently for different groups of people by age and gender. 
Table 1. Definitions and means of all variables. 
Variable 
Whole 
sample 
Women 
Age 18–44 
Women 
Age 45+ 
Men 
Age 18–44 
Men 
Age 45+ 
Quit  0.098  0.102  0.101  0.087  0.098 
TDT coverage (Tobacco 
Dependence Treatment) 
1.916 
(2.38) 
1.712 
(2.31) 
2.155 
(2.46) 
1.852 
(2.34) 
2.250 
(2.47) 
Age 
41.464 
(15.45) 
30.913 
(7.14) 
58.364 
(9.92) 
32.560 
(7.66) 
57.644 
(9.86) 
Family income (in 1,000 
dollars) 
13.894 
(13.63) 
13.660 
(13.02) 
12.486 
(12.92) 
15.784 
(15.05) 
14.601 
(14.53) 
Household size 
2.960 
(1.74) 
3.564 
(1.59) 
2.035 
(1.46) 
3.290 
(1.83) 
2.139 
(1.52) 
Number of years smoked 
24.648 
(14.99) 
14.806 
(7.39) 
39.284 
(10.94) 
16.771 
(8.19) 
41.229 
(10.89) 
Married  0.272  0.221  0.198  0.403  0.378 
Employed  0.275  0.349  0.128  0.372  0.160 
Female  0.674  1  1  0  0 
Race           
  White (omitted)  0.708  0.699  0.718  0.734  0.710  
  Black  0.169  0.186  0.178  0.114  0.148 
  Hispanic  0.063  0.056  0.056  0.074  0.078 
  Others  0.060  0.059  0.048  0.078  0.064 
Education           
  Less than high 
school (omitted) 
0.398  0.346  0.461  0.390  0.458 
  High school  0.370  0.411  0.316  0.383  0.319 
  Some college  0.197  0.225  0.171  0.190  0.167 
  College +  0.035  0.018  0.052  0.037  0.056 
Year           
  1993 (omitted)  0.203  0.238  0.162  0.207  0.152 
  1996  0.215  0.224  0.210  0.230  0.182 
  1999  0.174  0.162  0.190  0.167  0.196 
  2001  0.035  0.031  0.031  0.034  0.048 
  2002  0.164  0.151  0.171  0.152  0.208 
  2003  0.209  0.194  0.236  0.210  0.214 
Number of observations  5323  2450  1139  862  872 
Notes: Standard deviations of continuous variables are in parentheses. 
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5. Results and Discussion 
 
5.1. Descriptive Results 
 
CPS-TUS 2003 data provide information about methods used to try to quit smoking. Table 2 reports 
the usage of TDT in the past year among Medicaid recipients. Column 1 reports, among those who 
used TDT, how many of them lived in a state covering TDT. Column 2 and 3 report how many 
Medicaid smokers used TDT in the past year, only Column 2 relating to states covering TDT, while 
Column  3  relating  to  states  not  covering  TDT.  Medicaid  recipients  who  used  medication  to  quit 
smoking were more likely to live in a state where Medicaid program covered that medication. On 
average, among Medicaid recipients who used medication as cessation aids, more than two-thirds lived 
in  states  where  the  medication  was  covered  by  Medicaid.  Such  a  pattern  was  not  seen  among 
counseling users who sought cessation aids—only 18.2% users lived in states where such counseling 
was covered by Medicaid. One possible reason is that the counseling questions asked in CPS survey 
may not match to the services covered by Medicaid. Column 2 and 3 suggest that smokers living in a 
state covering medication are more likely to use it, with 19.3% having used this aid, while only 13.6% 
Medicaid  smokers  living  in  states  not  covering  TDT  used  the  aid.  This  result  is  consistent  with 
previous study [26]. 
Table 2. Usage of TDT in the past year among Medicaid recipients, CPS-TUS 2003. 
TDT usage  1  2  3  N * 
Medication          
- Nicotine gum  60.9%  8.2%  7.3%  69 
- Nicotine patch  68.0%  19.3%  13.6%  150 
- Nicotine nasal spray  87.5%  1.4%  1.3%  8 
- Nicotine inhaler  60.0%  3.0%  2.6%  25 
- Zyban, Buproprion, Wellbutrin  84.1%  9.0%  4.7%  69 
Total  69.8%      321 
Counselling         
- Telephone  5.9%  1.0%  2.0%  17 
- Group  11.8%  1.2%  2.1%  17 
- Individual  33.3%  2.6%  2.3%  21 
Total  18.2%      55 
Notes: N is the number of observations. 
 
5.2. Multivariate Regression Results 
 
Tables 3 reports the probit model results for different groups from three specifications, namely the 
baseline specification (Baseline), the state fixed effects specification (State FE) which includes all the 
independent variables from Baseline plus state dummies, and the anti-smoking sentiment specification 
(Sentiment)  which  includes  all  the  independent  variables  from  Baseline  plus  the  anti-smoking 
sentiment index. If individual disturbances are correlated within a state, the usual estimates of standard 
errors will be biased downward. Therefore, robust standard errors adjusted for clustering at the state Int. J. Environ. Res. Public Health 2009, 6                 
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level are used to address this problem. Only estimates of TDT are presented in Table 3, as TDT is the 
main concern of this study, but models actually control for all the variables listed in Table 1. The full 
results are available upon request. 
TDT is statistically significant for women of age 18–44 across all three specifications. The results 
suggest that among female Medicaid smokers aged 18–44, those having higher level of coverage of 
cessation products were more likely to quit smoking. The marginal effect of Sentiment specification 
suggests  that,  if  a  state  Medicaid  program  covers  one  more  form  of TDT, the smoking cessation 
probability would increase by 0.7 percentage points, or a 7% increase in the baseline cessation rate. 
However, TDT is not statistically significant for any other group. 
The  effects  of  anti-smoking  sentiment  are  as  expected.  The  positive  coefficient  indicates  
smokers are more likely to quit in states with high anti-smoking sentiment than in states with low  
anti-smoking sentiment.  
Table 3. Probit model of smoking cessation. 
 
Baseline  State FE  Sentiment  Baseline 
State 
FE 
Sentiment 
Female  Age 18–44  Age 45+ 
TDT 
coverage 
0.009*** 
(0.004) 
0.007* 
(0.004) 
0.007** 
(0.003) 
0.003 
(0.005) 
0.007 
(0.006) 
0.003 
(0.005) 
Anti-Smoking 
sentiment 
   
0.126*** 
(0.045) 
   
0.015 
(0.064) 
N  2,450  1,139 
 
Male  Age 18–44  Age 45+ 
TDT 
coverage 
0.003 
(0.005) 
–0.005 
(0.010) 
0.001 
(0.005) 
–0.002 
(0.006) 
–0.011 
(0.010) 
–0.002 
(0.006) 
Anti-Smoking 
sentiment 
   
0.067* 
(0.038) 
   
–0.008 
(0.058) 
N  862  872 
Notes: The table lists marginal effects, with standard errors in parentheses. Statistical significance 
(based on a two-tailed test) is indicated with asterisks: *** P < 0.01, ** P < 0.05, * P < 0.1. N is 
the number of observations. 
 
5.3. Robustness Check 
 
One explanation of why the effect of TDT coverage on cessation is only significant for women  
of 18–44 years of age is that many women in this age group are enrolled in Medicaid program because 
of pregnancy. In ten states in 2000, TDT coverage by Medicaid was for pregnant smokers only [27]. 
They quit smoking under the concerns of adverse health effect on their babies and risk of spontaneous 
abortion  [28-30].  A  report  by  National  Center  for  Chronic  Disease  Prevention  and  Health  
Promotion  [31]  said  ―Compared  with  women  who  do  not  smoke,  women  who  smoke  prior  to 
pregnancy are about twice as likely to experience a delay in conception and have approximately 30% 
higher  odds  of  being  infertile;  women  who  smoke  during  pregnancy  are  about  twice  as  likely  to Int. J. Environ. Res. Public Health 2009, 6                 
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experience  premature  rupture  of  membranes,  placental  abruption,  and  placenta  previa  during 
pregnancy.‖  Pregnant  smokers  are  likely  to  be  advised  by  health professionals  to  quit  as  early as 
possible [32]. 
CPS-TUS data do not directly provide information on pregnancy. However, if a woman had a child 
under age 1 in March 2004, then she must be pregnant in March 2003. As discussed before, part of 
CPS survey respondents in March 2003 can be linked to March 2004. Therefore, we may control for 
whether a woman was pregnant or not for a subset of the sample. The regression results are reported in 
Table 4. The estimated coefficient on TDT coverage is still positive and statistically significant at 10% 
level. As the subgroup sample size is only one forth of the original one, the standard errors are greater 
in this model. Being pregnant increases the probability of quitting smoking among women aged 18–44 
by 13 percentage points.  
Table 4. Probit model of smoking cessation, age 18–44 women, controlling for pregnancy. 
  Baseline  State FE  Sentiment 
TDT 
coverage 
0.015** 
(0.008) 
0.008 
(0.013) 
0.011* 
(0.006) 
Pregnant 
0.129*** 
(0.051) 
0.139** 
(0.070) 
0.129*** 
(0.051) 
Anti-Smoking 
sentiment 
   
0.180** 
(0.079) 
N  694 
Notes:  The  table  lists  marginal  effects,  with  standard  errors  in  parentheses. 
Statistical  significance  (based  on  a  two-tailed  test)  is  indicated  with  asterisks:  
*** P < 0.01, ** P < 0.05, * P < 0.1. N is the number of observations. 
 
5.4. Effect of TDT Coverage on Initiation  
 
One might think that TDT coverage might make cessation relatively easy and thus induce non-
smokers to try smoking. Therefore, smoking initiation might increase because of this moral hazard. 
This  paper  also  examines  the  possible  effect  by  estimating  smoking  initiation  models,  which  are 
similar to cessation models hereinbefore and use the same data, only the dependent variable Y to be 1 
if a respondent initiated smoking in the past 12 months. Table 5 presents the results. TDT coverage is 
negative and statistically significant for women aged 18–44 in all three specifications. So contrary to 
what one might think, TDT coverage reduces the possibility of smoking initiation for non-smokers 
especially for women in the age of 18–44. Probably this is because when health professionals and 
social workers inform the Medicaid recipients about the coverage of cessation aids, they would also 
talk about the adverse health consequences of smoking. Therefore, not only more smokers quit but also 
fewer non-smokers start smoking. TDT coverage is not statistically significant for other three groups. Int. J. Environ. Res. Public Health 2009, 6                 
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Table 5. Probit model of smoking initiation.  
 
Baseline  State FE  Sentiment  Baseline 
State 
FE 
Sentiment 
Female  Age 18–44  Age 45+ 
TDT 
coverage 
–0.004** 
(0.002) 
–0.005** 
(0.002) 
–0.003** 
(0.001) 
0.0002 
(0.001) 
0.001 
(0.001) 
0.0002 
(0.001) 
Anti-Smoking 
sentiment 
   
–0.018 
(0.017) 
   
–0.014 
(0.010) 
N  5,469  5,250 
 
Male  Age 18–44  Age 45+ 
TDT 
coverage 
–0.001 
(0.002) 
0.001 
(0.004) 
–0.001 
(0.002) 
0.0006 
(0.001) 
–0.0006 
(0.003) 
0.0005 
(0.001) 
Anti-Smoking 
sentiment 
   
–0.013 
(0.019) 
   
0.008 
(0.011) 
N  1,658  2,209 
Notes: The table lists marginal effects, with standard errors in parentheses. Statistical significance 
(based on a two-tailed test) is indicated with asterisks: *** P < 0.01, ** P < 0.05, * P < 0.1. N is 
the number of observations. 
 
6. Conclusions and Discussions 
 
This study finds evidence that state Medicaid coverage of TDT has a positive impact on smoking 
cessation for women aged 18–44. For one more form of coverage, cessation rate will increase by 7%. 
Even when pregnancy is controlled for in the model, the effect still exists. The results are consistent 
with a recent study by Peterson et al. [18], who find women in states with extensive coverage of 
cessation aids had 18% higher probability of quitting compared to women in states with no coverage. 
There is no evidence that such effect exists for men or older women.  
There  are  several  reasons  to  explain  why  TDT  coverage  may  not  lead  to  significant  smoking 
cessation for men and older women. First, smokers interested in quitting may be not aware of that they 
can obtain financial assistance for tobacco-dependence treatments from Medicaid, as several studies 
find that a majority of Medicaid smokers are unaware of the program benefit providing coverage for 
TDT  [15,33,34].  Second,  most  quit  attempts  are  made  without  pharmaceutical  cessation  aids.  
CPS-TUS 2003 suggests only 20% smokers ever used NRT in a quit attempt in the past year. Third, 
many smokers do not use medications because of safety concerns [6]. Finally, Medicaid may limit the 
number of courses of medication a person can obtain in a given time period, which may deter smokers 
from making multiple quit attempts [16]. 
The central implication of this study is that, simply changing the insurance coverage alone is not 
sufficient to substantially reduce smoking among Medicaid recipients. More work is needed to improve 
successful quitting among Medicaid smokers besides providing coverage of pharmaceutical therapies 
and  counseling.  Medicaid  social  workers  should  make  efforts  to  inform  the  beneficiaries  of  the 
smoking-cessation  treatment  coverage.  Medicaid  programs  in  each  state  might  consider  providing Int. J. Environ. Res. Public Health 2009, 6                 
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more educational materials to help smokers understand the risks and benefits of NRT products, to 
improve smokers’ knowledge about the safety and efficiency of these medications.  
 
Acknowledgements 
 
This  research  was  supported  by  the  Scientific  Research  Foundation  for  the  Returned  Overseas 
Chinese Scholars, State Education Ministry, China.  
 
References and Notes 
 
1.  Lillard, D.R.; Plassmann, V.; Kenkel, D.; Mathios, A. Who kicks the habit and how they do it: 
socioeconomic differences across methods of quitting smoking in the USA. Soc. Sci. Med. 2007, 
64, 2504-2519. 
2.  Etter,  J.F.;  Stapleton,  J.A.  Nicotine  replacement  therapy  for  long-term  smoking  cessation:  a  
meta-analysis. Tob. Control 2006, 15, 280-285. 
3.  Hughes, J.R.; Goldstein, M.G.; Hurt, R.D.; Shiffman, S. Recent advances in the pharmacotherapy 
of smoking. JAMA 1999, 281, 72-76. 
4.  US Department of Health and Human Services. A clinical practice guideline for treating tobacco 
use and dependence: 2008 update. A U.S. Public Health Service report. Am. J. Prev. Med. 2008, 
35, 158-176. 
5.  Cummings, K.M.; Hyland, A. Impact of nicotine replacement therapy on smoking behavior. Annu 
Rev. Public Health 2005, 26, 583-599. 
6.  Bansal, M.A.; Cummings, K.M.; Hyland, A.; Giovino, G.A. Stop-smoking medications: who uses 
them, who misuses them, and who is misinformed about them? Nicotine. Tob. Res. 2004, 6 Suppl 
3, S303-310. 
7.  Centers  for  Medicare  &  Medicaid  Services.  Medicaid  Program—General  Information;  US 
Department of Health and Human Services: Washington, DC, USA, 2008. 
8.  Miller,  L.S.;  Zhang,  X.;  Novotny,  T.;  Rice,  D.P.;  Max,  W.  State  estimates  of  Medicaid 
expenditures attributable to cigarette smoking, fiscal year 1993. Public Health Rep. 1998, 113, 
140-151. 
9.  American  Legacy  Foundation.  Saving  Lives,  Saving  Money:  Why  States  Should  Invest  in  a 
Tobacco-Free Future; American Legacy Foundation: Washington, DC, USA, 2002. 
10.  Maciosek, M.V.; Coffield, A.B.; Edwards, N.M.; Flottemesch, T.J.; Goodman, M.J.; Solberg, L.I. 
Priorities among effective clinical preventive services: results of a systematic review and analysis. 
Am. J. Prev. Med. 2006, 31, 52-61. 
11.  Samet, J.M. The 1990 report of the surgeon general: the health benefits of smoking cessation. Am. 
Rev. Respir. Dis. 1990, 142, 993-994. 
12.  Flynn, B.S.; Goldstein, A.O.; Solomon, L.J.; Bauman, K.E.; Gottlieb, N.H.; Cohen, J.E.; Munger, 
M.C.; Dana, G.S. Predictors of state legislators' intentions to vote for cigarette tax increases. Prev. 
Med .1998, 27, 157-165. Int. J. Environ. Res. Public Health 2009, 6                 
 
 
3154 
13.  Ky.  May  Allow  Medicaid  Payment  for  Stop-Smoking  Therapies;  Available  online: 
http://www.jointogether.org/news/headlines/inthenews/2006/ky-may-allow-medicaid.html 
(accessed on June 16, 2009).  
14.  Curry,  S.J.;  Grothaus,  L.C.;  McAfee,  T.;  Pabiniak,  C.  Use  and  cost  effectiveness  of  
smoking-cessation services under four insurance plans in a health maintenance organization. N. 
Engl. J. Med. 1998, 339, 673-679. 
15.  Boyle, R.G.; Solberg, L.I.; Magnan, S.; Davidson, G.; Alesci, N.L. Does insurance coverage for 
drug therapy affect smoking cessation? Health Aff. 2002, 21, 162-168. 
16.  Centers  for Disease Control  and Prevention. State Medicaid coverage for tobacco-dependence 
treatments—United States, 2005. MMWR 2006, 55, 1194-1197. 
17.  Schauffler,  H.H.;  McMenamin,  S.;  Olson,  K.;  Boyce-Smith,  G.;  Rideout,  J.A.;  Kamil,  J. 
Variations in treatment benefits influence smoking cessation: results of a randomised controlled 
trial. Tob. Control 2001, 10, 175-180. 
18.  Petersen, R.; Garrett, J.M.; Melvin, C.L.; Hartmann, K.E. Medicaid reimbursement for prenatal 
smoking intervention influences quitting and cessation. Tob. Control 2006, 15, 30-34. 
19.  Centers  for Disease Control  and Prevention. State Medicaid coverage for tobacco-dependence 
treatments—United States, 1994-2002. MMWR 2004, 53, 54-57. 
20.  Greene, W.H. Econometric Analysis; 3rd ed.; Prentice Hall: Upper Saddle River, NJ, USA, 1997; 
pp. 418-427. 
21.  Kennedy,  P.  A  Guide  to  Econometrics;  3rd  ed.;  Blackwell  Publishers:  Oxford,  UK,  1992;  
pp. 183-184. 
22.  Decicca, P.; Kenkel, D.; Mathios, A.; Shin, Y.J.; Lim, J.Y. Youth smoking, cigarette prices, and 
anti-smoking sentiment. Health Econ. 2008, 17, 733-749. 
23.  Liu, F. Cutting through the smoke: separating the effect of price on smoking initiation, relapse and 
cessation. Appl. Econ. 2009, doi: 10.1080/00036840801964880. 
24.  Curry,  S.J.;  Sporer,  A.K.;  Pugach,  O.;  Campbell,  R.T.;  Emery,  S.  Use  of  tobacco  cessation 
treatments among young adult smokers: 2005 National Health Interview Survey. Am. J. Public 
Health 2007, 97, 1464-1469. 
25.  Shiffman, S.; Brockwell, S.E.; Pillitteri, J.L.; Gitchell, J.G. Individual differences in adoption of 
treatment for smoking cessation: demographic and smoking history characteristics. Drug Alcohol 
Dependence 2008, 93, 121-131. 
26.  Kaper,  J.;  Wagena,  E.J.;  Willemsen,  M.C.;  van  Schayck,  C.P.  Reimbursement  for  smoking 
cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005, 
100, 1012-1020. 
27.  Ibrahim, J.K.; Schauffler, H.H.;  Barker, D.C.; Orleans, C.T. Coverage of tobacco dependence 
treatments for pregnant women and for children and their parents. Am. J. Public Health 2002, 92, 
1940-1942. 
28.  Adams, E.K.; Miller, V.P.; Ernst, C.; Nishimura, B.K.; Melvin, C.; Merritt, R. Neonatal health 
care costs related to smoking during pregnancy. Health Econ. 2002, 11, 193-206. 
29.  Ness, R.B.; Grisso, J.A.; Hirschinger, N.; Markovic, N.; Shaw, L.M.; Day, N.L.; Kline, J. Cocaine 
and tobacco use and the risk of spontaneous abortion. N. Engl. J. Med. 1999, 340, 333-339. Int. J. Environ. Res. Public Health 2009, 6                 
 
 
3155 
30.  Oncken, C.; Kranzler, H.; O'Malley, P.; Gendreau, P.; Campbell, W.A. The effect of cigarette 
smoking on fetal heart rate characteristics. Obstet. Gynecol. 2002, 99, 751-755. 
31.  Centers for Disease Control and Prevention. Preventing Smoking and Exposure to Secondhand 
Smoke Before, During, and After Pregnancy; National Center for Chronic Disease Prevention and 
Health Promotion: Atlanta, GA, USA, 2007. 
32.  West, R.; McNeill, A.; Raw, M. Smoking cessation guidelines for health professionals: an update. 
Health Education Authority. Thorax 2000, 55, 987-999. 
33.  McMenamin,  S.B.;  Halpin,  H.A.;  Bellows,  N.M.  Knowledge  of  Medicaid  coverage  and 
effectiveness of smoking treatments. Am. J. Prev. Med. 2006, 31, 369-374. 
34.  Murphy, J.M.; Mahoney, M.C.; Hyland, A.J.; Higbee, C.; Cummings, K.M. Disparity in the use of 
smoking cessation pharmacotherapy among Medicaid and general population smokers. J. Public 
Health Manag. Pract. 2005, 11, 341-345. 
 
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This  article  is  an  open-access  article  distributed  under  the  terms  and  conditions  of  the  Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 